School of Medicine


Showing 1-10 of 54 Results

  • Scott S. Hall, PhD, BCBA-D

    Scott S. Hall, PhD, BCBA-D

    Associate Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences) at the Stanford University Medical Center

    Current Research and Scholarly InterestsMy primary area of scholarly and clinical interest is the pathogenesis of problem behaviors shown by individuals diagnosed with intellectual and developmental disabilities (IDD), particularly those with neurogenetic forms of IDD, such as fragile X syndrome, Cornelia de Lange syndrome and Prader-Willi syndrome. My work aims to both advance understanding of these disorders and to identify effective new treatment approaches for pediatric and adult patient populations by state-of-the-art methodologies, such as brain imaging, eye tracking and functional analysis to determine how environmental and biological factors affect the development of aberrant behaviors in these syndromes. The end goal of my research is to create patient-specific methods for treating the symptoms of these disorders.

  • Joachim Hallmayer

    Joachim Hallmayer

    Professor of Psychiatry and Behavioral Sciences

    Current Research and Scholarly InterestsPrincipal Investigator
    Infrastructure to facilitate discovery of autism genes
    The purpose of this project is to facilitate the discovery of the genes that contribute autism by maintaining an infrastructure which research groups studying the genetics of autism can work collaboratively. This will be
    accomplished through workshops, a Virtual Private Network, and access to a database that includes phenotype and genotype data from all participating groups.

    Principal Investigator
    A California Population-Based Twin Study of Autism
    This will address several fundamental questions: (1) What is the heritability of autism (2) What is the contribution of genetic factors to variation in symptom dimensions? (3) Is there a continuum between the quantitative neurocognitive traits and clinical disorder? (4) What proportion of the variance in the neurocognitive traits is accounted for by genetic and non-genetic factors?

    Co-Investigator
    Center for Integrating Ethics in Genetics Research(Cho)
    The goal of this project is to serve as a center of excellence in neurogenetics research, to develop a national model for bench, to bedside research ethics consultation, and to provide training opportunity in biomedical ethics.

    Co-Investigator
    Gene, Brain and Behavior in Turner Syndrome(Reiss)
    The primary objective of this project is to use advanced, multi-modal magnetic resonance imaging (MRI) techniques, analyses of X chromosome parent-of-origin and cognitive-behavioral assessment to elucidate the effects of monosomy and X-linked imprinting on neurodevelopment and neural function in a large cohort of young girls with Turner syndrome, pre-estrogen replacement.

    Project Director
    Project F: Genomic Analysis in narcolepsy cataplexy
    The goal of the project is to locate genes outside the HLA region that influence susceptibility to narcolepsy. In order to localize these genes we will carry out a linkage and association study in the most extensive world-wide collection of DNAs from well-characterized patients with narcolepsy and their families.

  • Casey H. Halpern, MD

    Casey H. Halpern, MD

    Assistant Professor of Neurosurgery and, by courtesy, of Neurology and of Psychiatry and Behavioral Sciences at the Stanford University Medical Center

    Current Research and Scholarly InterestsWe are currently investigating the effects of deep brain stimulation in obesity using mouse models of human behavior. Many obese individuals exhibit behavioral disinhibition, a clinical feature of many neurologic and psychiatric conditions. We are dissecting the mesocorticolimbic circuit with novel techniques including optogenetics.

  • Maryam Sarah Hamidi, PhD

    Maryam Sarah Hamidi, PhD

    Soc Science Rsch Prof 3, Psych/General Psychiatry and Psychology (Adult)

    Current Role at StanfordAssociate Director of Scholarship & Health Promotion at Stanford Medicine WellMD Center
    Research Professional at Department of Psychiatry and Behavioral Sciences

  • Mindy Hantke

    Mindy Hantke

    Admin Services Administrator, Psychiatry and Behavioral Sciences

    Current Role at StanfordWeb & Communications Administration
    Psychiatry and Behavioral Sciences (http://med.stanford.edu/psychiatry.html)

  • Antonio Hardan, M.D.

    Antonio Hardan, M.D.

    Professor of Psychiatry and Behavioral Sciences at the Stanford University Medical Center

    Current Research and Scholarly InterestsThe neurobiology of autism
    Neuroimaging in individuals with autism
    Psychopharmacological treatment of children and adults with autism and/or developmental disorders

  • Kate Hardy, Clin.Psych.D

    Kate Hardy, Clin.Psych.D

    Clinical Assistant Professor, Psychiatry and Behavioral Sciences

    BioKate Hardy is a California Licensed Psychologist who has specialized in working with individuals with psychosis for over 15 years in both research and clinical settings. Dr. Hardy received her doctorate in clinical psychology from the University of Liverpool, United Kingdom. She has worked in specialist early psychosis services in both the UK and the US, including UCSF’s Prodrome Assessment Research and Treatment (PART) program, where she completed her post-doctoral fellowship, and as Clinical Director for the Prevention and Recovery from Early Psychosis (PREP) program. Dr. Hardy has significant experience in providing CBTp to individuals with early psychosis, and those at risk of developing psychosis, in both individual and group settings and integration of this clinical intervention to broader systems and staff teams. She has led multiple trainings and workshops in CBTp to a wide variety of audiences including community clinicians, psychiatrists, and families, and provides ongoing supervision and consultation in this approach. Dr. Hardy is also involved in the implementation of national strategies to increase dissemination of early psychosis models with the aim of bringing these cutting edge treatments to a broader population.